Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sumitomo Pharma CoDNPUF 60 Equity-to-Asset is 0.36 as of Mar. 2026, which is 16% below its 10-year median of 0.43. GuruFocus rates DNPUF with a GF Score™ of 60/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Sumitomo Pharma Co ranks worse than 67.59% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sumitomo Pharma Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $1,843 Mil. Sumitomo Pharma Co's Total Assets for the quarter that ended in Mar. 2026 was $5,070 Mil.
Therefore, Sumitomo Pharma Co's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.36.
The historical rank and industry rank for Sumitomo Pharma Co's Equity-to-Asset or its related term are showing as below:
DNPUF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17 Med: 0.43 Max: 0.6
Current: 0.48
During the past 13 years, the highest Equity to Asset Ratio of Sumitomo Pharma Co was 0.60. The lowest was 0.17. And the median was 0.43.
DNPUF's Equity-to-Asset is ranked worse than 67.59% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs DNPUF: 0.48
Sumitomo Pharma Co (OTCPK:DNPUF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sumitomo Pharma Co Equity-to-Asset Related Terms
Sumitomo Pharma Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Sumitomo Pharma Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sumitomo Pharma Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (DNPUF) has a Equity-to-Asset of 0.36 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sumitomo Pharma Co and its competitors. This is 16% below median its historical median of 0.43. Over the past decade, Sumitomo Pharma Co's Equity-to-Asset has ranged from 0.17 to 0.60. According to the industry distribution chart, Sumitomo Pharma Co ranks #680 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 67.6%.
Is Sumitomo Pharma Co's Equity-to-Asset too high?
Sumitomo Pharma Co's current Equity-to-Asset of 0.36 is 16% below median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.60. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Sumitomo Pharma Co's value of 0.36 is 40% below this industry median. Based on the distribution chart, Sumitomo Pharma Co ranks #680 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sumitomo Pharma Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sumitomo Pharma Co ranks #680 out of 1006 companies for Equity-to-Asset. This places Sumitomo Pharma Co in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Sumitomo Pharma Co's value of 0.36 is 40% below this benchmark. Historically, Sumitomo Pharma Co's own Equity-to-Asset has ranged from 0.17 to 0.60 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 0.60, Sumitomo Pharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sumitomo Pharma Co's current Equity-to-Asset of 0.36 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sumitomo Pharma Co and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sumitomo Pharma Co's current Equity-to-Asset is 0.36, which is 16% below median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $9.27 — trading 64.9% above its estimated fair value. The current Equity-to-Asset is 0.36, which is 16% below median its 10-year median of 0.43 and 40% below the Drug Manufacturers industry median of 0.60. Sumitomo Pharma Co's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current Equity-to-Asset is 0.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?
Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued.
The current stock price of $9.27 is trading 64.9% above its estimated GF Value™ of $5.62.
GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.
Key valuation signals for DNPUF:
Equity-to-Asset: 0.36 (16% below median its 10-year median of 0.43)
GF Value™: $5.62 vs. price of $9.27 (64.9% above fair value)
Industry Position: 40% below the Drug Manufacturers median (#680 of 1006)
No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
60GF Score
Get the complete analysis for DNPUF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNPUF has been successfully added to your 
